98%
921
2 minutes
20
Long bone metastases are common in patients with metastatic renal cell carcinoma (RCC). One potential surgical treatment option is resection and megaprosthetic reconstruction. However, implant complications and survival are poorly understood. This study analyzes patient and implant survival as well as associated risk factors. This is a retrospective study from a single academic center, analyzing 86 patients that underwent resection and megaprosthetic reconstruction performed between 1993 and 2017. The most common location of megaprosthetic reconstruction was the proximal femur (PFR) in 38% (33 of 86) of patients. We calculated overall patient survival and associated risk factors using the Kaplan-Meier method and implant survivorship using a competing risk analysis. A total of 73% (63/86) of patients died of their disease after a median of 19 (IQR 9-37) months following surgery, and a median of 71 (IQR 31-132) months after the initial diagnosis of RCC. The overall survival probability was 29% (95% CI 18-40%) five years after surgery. The five-year risk of revision surgery (within a competing risk framework) was 18% (95% CI 11-28). A total of 8% (7 of 86) of patients underwent an exchange of the implant itself. Patients with total bone replacements had a higher revision risk (SHR 19.46 (95% CI 6.9-54.9), < 0.01). Furthermore, the revision risk was higher with increasing reconstruction length per mm (SHR 1.01 (95% CI 1.01-1.02), = 0.03) and prolonged surgical time per minute (SHR: 1.01 (95% CI 1.0-1.02), < 0.01). Local postoperative radiation treatment (RTX) was associated with an increased risk for revisions (SHR 2.59 (95% CI 0.96-6.95), = 0.06). Modular megaprostheses demonstrated a fairly low risk of implant revision although postoperative radiation therapy and total bone replacements are associated with an increased risk.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191405 | PMC |
http://dx.doi.org/10.3390/cancers17121982 | DOI Listing |
SICOT J
August 2025
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, Rimini Street, Chaidari 124 62, Athens, Greece.
Background: Proximal femoral megaprosthetic reconstruction is a well-established solution for extensive bone loss in the hip region. Despite its utility in limb salvage, it carries notable complication rates, reported between 30% and 40%, along with increased morbidity and mortality. This study evaluated implant and patient survival, failure modes, and associated risk factors.
View Article and Find Full Text PDFCase Rep Oncol
June 2025
Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Introduction: Giant cell tumors of bone (GCTBs) are locally aggressive tumors that can induce pathological fractures. Previous reports suggest that denosumab induces intratumoral ossification in β-catenin positive GCTB. However, its effect on the complete resection of GCTB with extraskeletal lesions remains unclear.
View Article and Find Full Text PDFCancers (Basel)
June 2025
Department of Orthopedics and Tumor Orthopedics, Muenster University Hospital, Albert-Schweitzer-Campus 1, 48149 Muenster, Germany.
Long bone metastases are common in patients with metastatic renal cell carcinoma (RCC). One potential surgical treatment option is resection and megaprosthetic reconstruction. However, implant complications and survival are poorly understood.
View Article and Find Full Text PDFRev Bras Ortop (Sao Paulo)
February 2025
Departamento de Ortopedia e Trauma, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria,Lisboa, Portugal.
Surgical management for bone tumors is aggressive in nature and frequently followed by wound-related complications (WRCs). To minimize these events, different strategies have been employed, with closed-incision negative-pressure wound therapy (ciNPWT) emerging as a potential adjuvant. With this study we intend to assess the impact of this technique in minimizing WRCs in patients with proximal and distal femur tumors treated with megaprosthesis.
View Article and Find Full Text PDFJ Arthroplasty
April 2025
Musculoskeletal Oncology Service, Department of Orthopaedic Surgery Massachusetts General Hospital Boston, Harvard Medical School, Boston, Massachusetts.
Background: Serum biomarkers and synovial fluid analysis are valuable tools for the preoperative diagnosis of periprosthetic joint infections (PJIs). However, the literature on their utility in megaprostheses is limited. Our study aimed to assess the diagnostic performance and accuracy of four laboratory tests for diagnosing PJI in patients who have megaprostheses.
View Article and Find Full Text PDF